Quetiapine

Summary

Quetiapine (CHEMBL716) is an approved small-molecule serotonergic antagonist (ATC N05AH04) targeting HTR1A, DRD2, and HRH1; indicated across 30 conditions including psychotic disorder and schizoaffective disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AH04
• Targets: 8 (HTR1A, DRD2, HRH1…)
• Indications: 30 conditions
• Clinical trials: 253
• Chemistry: 383.5 Da · C21H25N3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL716
Name	Quetiapine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5002
ChEBI	CHEBI:8707
ATC	N05AH04
Molecular formula	C21H25N3O2S
Molecular weight	383.5
InChIKey	URKOMYMAXPYINW-UHFFFAOYSA-N

SMILES: C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42

IUPAC name: 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol

Pharmacological roles (ChEBI): serotonergic antagonist, dopaminergic antagonist, histamine antagonist, adrenergic antagonist, second generation antipsychotic.

Also known as: Atrolak xl, Biquelle xl, Brancico xl, Ebesque xl, Mintreleq xl, Norsic, NSC-758918, Psyquet xl, Quetiapina, Quetiapine, Quetiapine extended release, Seotiapim xl

Parent form; salt/anhydrous children: CHEMBL1200911, CHEMBL3188993

Patent coverage: 7,009 distinct patent families (26,465 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 26,309 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR1A	5-HT1A receptor	Full agonist	6.6	0%	P08908
DRD2	D2 receptor	Antagonist	7.2	0%	P14416
HRH1	H1 receptor	Antagonist	8.7	0%	P35367
HTR1D	5-HT1D receptor	Full agonist	5.7	0%	P28221
HTR1E	5-ht1e receptor	Full agonist	5.9	0%	P28566
HTR1F	5-HT1F receptor	Full agonist	5.6	0.1%	P30939
HTR2A	5-HT2A receptor	Full agonist	7	0%	P28223
SLC6A2	NET	Inhibition	6.03	0.4%	P23975

Broader ChEMBL bioactivity targets: 45 (assay-derived). Sample: Prelamin-A/C, Muscarinic acetylcholine receptor M4, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, Sodium channel protein type 5 subunit alpha, Beta-lactamase.

Bioactivity

ChEMBL activities: 158 potent at pChembl ≥ 5 of 168 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1D	8.35	Ki	4.5	nM	CHEMBL_ACT_673743
HRH1	8.34	Ki	4.6	nM	CHEMBL_ACT_7741714
ADRA1D	8.15	Ki	7	nM	CHEMBL_ACT_22435773
HRH1	8.06	Ki	8.7	nM	CHEMBL_ACT_2556769
HRH1	8	Ki	10	nM	CHEMBL_ACT_14543255
HRH1	8	Ki	10	nM	CHEMBL_ACT_16272774
HRH1	7.96	Ki	11	nM	CHEMBL_ACT_22435767
P15823	7.9	Ki	12.59	nM	CHEMBL_ACT_1925450
P15823	7.87	Ki	13.6	nM	CHEMBL_ACT_7741608
HRH1	7.72	Ki	19	nM	CHEMBL_ACT_437386
ADRA1A	7.7	Ki	20	nM	CHEMBL_ACT_16356858
HRH1	7.68	Ki	21	nM	CHEMBL_ACT_673746
P15823	7.61	IC50	24.5	nM	CHEMBL_ACT_7741607
HRH1	7.58	AC50	26	nM	CHEMBL_ACT_25212960
HTR2A	7.51	Ki	31	nM	CHEMBL_ACT_19101889
HTR2A	7.47	Ki	33.6	nM	CHEMBL_ACT_7743865
P43140	7.46	Ki	34.9	nM	CHEMBL_ACT_7741606
P31389	7.4	Ki	39.81	nM	CHEMBL_ACT_1925476
P31390	7.4	IC50	40	nM	CHEMBL_ACT_2147482
HRH1	7.4	IC50	39.6	nM	CHEMBL_ACT_7741713
ADRA2B	7.34	Ki	45.8	nM	CHEMBL_ACT_7741614
ADRA1D	7.32	Ki	47.5	nM	CHEMBL_ACT_7741610
CHRM1	7.25	Ki	56	nM	CHEMBL_ACT_673745
ADRA1D	7.24	Ki	58	nM	CHEMBL_ACT_437383
ADRA1A	7.22	AC50	60.7	nM	CHEMBL_ACT_25138503
ADRA2C	7.21	Ki	61.1	nM	CHEMBL_ACT_7741616
HTR2A	7.2	Ki	63.1	nM	CHEMBL_ACT_1925234
HTR7	7.2	Ki	63.1	nM	CHEMBL_ACT_1925394
DRD2	7.2	Ki	63.1	nM	CHEMBL_ACT_288601
DRD2	7.16	Ki	69	nM	CHEMBL_ACT_673737

Target pathways

Aggregated over 8 target gene(s): HTR1A, DRD2, HRH1, HTR1D, HTR1E, HTR1F, HTR2A, SLC6A2.

Top Reactome pathways

19 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
Signaling by GPCR	5	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
Class A/1 (Rhodopsin-like receptors)	5	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
Amine ligand-binding receptors	5	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
Serotonin receptors	5	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
GPCR ligand binding	5	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
GPCR downstream signalling	4	HTR1D, HTR1E, HTR1F, HTR2A
G alpha (i) signalling events	3	HTR1D, HTR1E, HTR1F
G alpha (q) signalling events	2	HRH1, HTR2A
Disease	1	SLC6A2
Transport of small molecules	1	SLC6A2
Histamine receptors	1	HRH1
Dopamine receptors	1	DRD2
R-HSA-425366	1	SLC6A2
SLC-mediated transmembrane transport	1	SLC6A2
SLC-mediated transport of neurotransmitters	1	SLC6A2
SLC transporter disorders	1	SLC6A2
Defective SLC6A2 causes orthostatic intolerance (OI)	1	SLC6A2
Disorders of transmembrane transporters	1	SLC6A2

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	7
chemical synaptic transmission	7
signal transduction	7
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	6
adenylate cyclase-inhibiting serotonin receptor signaling pathway	4
adenylate cyclase-activating G protein-coupled receptor signaling pathway	4
response to xenobiotic stimulus	3
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	3
serotonin receptor signaling pathway	2
positive regulation of cell population proliferation	2
adult behavior	2
regulation of behavior	2
G protein-coupled serotonin receptor signaling pathway	2
temperature homeostasis	2
intracellular calcium ion homeostasis	2

Indications & clinical

Indications

30 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407
schizoaffective disorder	4	MONDO:0005487	EFO:0005411
mood disorder	3	MONDO:0005371	EFO:0004247
anxiety	3	MONDO:0011918	EFO:0005230
mental disorder	3	MONDO:0005084	EFO:0000677
social phobia	3	MONDO:0001247	EFO:1001917
dementia	3	MONDO:0001627	HP:0000726
borderline personality disorder	3	MONDO:0001156	HP:0012076
delirium	3	MONDO:0045057	EFO:0009267
major depressive disorder	3	MONDO:0002009	MONDO:0002009
depressive disorder	3	MONDO:0002050	MONDO:0002050
bipolar disorder	3	MONDO:0004985	EFO:0009963
insomnia	2	MONDO:0013600	EFO:0004698
postpartum depression	2	MONDO:0005929	EFO:0007453
obsessive-compulsive disorder	2	MONDO:0008114	EFO:0004242
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
cannabis dependence	2	MONDO:0005689	EFO:0007191
obstructive sleep apnea syndrome	2	MONDO:0007147	EFO:0003918
Parkinson disease	2	MONDO:0005180	MONDO:0005180
alcohol abuse	2	MONDO:0002046	MONDO:0007079
anorexia nervosa	2	MONDO:0005351	MONDO:0005351
cocaine dependence	1	MONDO:0005186	EFO:0002610
drug-induced dyskinesia	1	MONDO:0006732	EFO:1000904
chronic kidney disease	1	MONDO:0005300	EFO:0003884
methamphetamine dependence	0	MONDO:0005419	EFO:0004701

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 253.

Phase distribution

Phase	Trials
PHASE4	95
PHASE3	69
Not specified	45
PHASE2	18
PHASE1	14
PHASE2/PHASE3	7
EARLY_PHASE1	3
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04373317	PHASE4	RECRUITING	Pimavanserin vs. Quetiapine for Treatment of Parkinson’s Psychosis
NCT05590637	PHASE4	RECRUITING	Comparing Antipsychotic Medications in LBD Over Time
NCT06433635	PHASE4	ACTIVE_NOT_RECRUITING	Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00043849	PHASE4	COMPLETED	Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048802	PHASE4	COMPLETED	Treatment and Outcome of Early Onset Bipolar Disorder
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00113295	PHASE4	COMPLETED	Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder
NCT00139074	PHASE4	TERMINATED	Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00181883	PHASE4	COMPLETED	Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder
NCT00182013	PHASE4	COMPLETED	Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder
NCT00182442	PHASE4	COMPLETED	Cognition, Functioning and Quality of Life
NCT00186043	PHASE4	COMPLETED	Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II
NCT00206102	PHASE4	COMPLETED	A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
NCT00208143	PHASE4	COMPLETED	Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
NCT00208819	PHASE4	COMPLETED	A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
NCT00214578	PHASE4	COMPLETED	Seroquel on Glucose Metabolism
NCT00223210	PHASE4	COMPLETED	An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence
NCT00223249	PHASE4	COMPLETED	Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
NCT00232336	PHASE4	COMPLETED	Quetiapine for Cocaine Use and Cravings
NCT00237393	PHASE4	COMPLETED	Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
NCT00237861	PHASE4	COMPLETED	Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
NCT00253266	PHASE4	COMPLETED	Venlafaxine Augmentation in Treatment Resistant Depression
NCT00254241	PHASE4	COMPLETED	Safety and Efficacy of Seroquel in First Episode Schizophrenia
NCT00255515	PHASE4	COMPLETED	Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
NCT00292370	PHASE4	COMPLETED	Quetiapine Augmentation for Treatment-resistant PTSD
NCT00295412	PHASE4	COMPLETED	The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
NCT00304616	PHASE4	COMPLETED	SWitching to Abilify Trial (SWAT)
NCT00330863	PHASE4	COMPLETED	Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
NCT00334035	PHASE4	COMPLETED	Antipsychotic Therapy and First Episode
NCT00370500	PHASE4	COMPLETED	Quetiapine and the Dopaminergic Epigenetic Control
NCT00375557	PHASE4	WITHDRAWN	Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer’s Dementia Patients
NCT00393978	PHASE4	COMPLETED	Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
NCT00397020	PHASE4	COMPLETED	Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes
NCT00407199	PHASE4	COMPLETED	The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment
NCT00423878	PHASE4	COMPLETED	Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (2) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for quetiapine and CYP2D6	DPWG	CYP2D6
Annotation of DPWG Guideline for quetiapine and CYP3A4	DPWG	CYP3A4	yes	yes

PharmGKB also curates 21 clinical and 99 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

878 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR1F, HTR2A, SLC6A2
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR1F, HTR2A, SLC6A2
RISPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR1F, HTR2A, SLC6A2
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR1F, HTR2A, SLC6A2
CYPROHEPTADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR1F, HTR2A, SLC6A2
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A, SLC6A2
ASENAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR2A, SLC6A2
ERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
METHYLERGONOVINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR1F, HTR2A
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR1F, HTR2A
RIZATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HRH1, HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
ZIPRASIDONE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR2A, SLC6A2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, SLC6A2
AZELASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1D, HTR1E, HTR2A, SLC6A2
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, SLC6A2
MIANSERIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, SLC6A2
NEFAZODONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A, SLC6A2
YOHIMBINE	ChEMBL + PubChem	Phase 3 (approved)	DRD2, HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
LYSERGIDE	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A
PENFLURIDOL	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1D, HTR2A, SLC6A2
RITANSERIN	ChEMBL	Phase 2	DRD2, HRH1, HTR1A, HTR1E, HTR2A, SLC6A2
AMITRIPTYLINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
CANNABIDIOL	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HTR1A, HTR1E, HTR2A, SLC6A2
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1E, HTR2A
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
SUMATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
ZOLMITRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1D, HTR1E, HTR1F, HTR2A
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
BENPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
BROMPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
CABERGOLINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
CINNARIZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
CLEMASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
DIBENZEPIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
DOXEPIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
DULOXETINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
EBASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
HALOPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
ILOPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
IPRINDOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
KETANSERIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR1D, HTR2A
LOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
LURASIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
MAPROTILINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
OXYPERTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
PERPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
PHENOXYBENZAMINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2
PIMOZIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR1A, HTR2A, SLC6A2